Emergent BioSolutions Inc.

NYSE:EBS

Biotechnology

Healthcare
$5.50 -2.58%

-$0.21 today

Market cap
$282.78M
Beta
2.33
P/E (TTM)
-47.9
EPS (TTM)
-$0.17
52W Low $5.62High $14.06

Volume 0.82M

Average 0.78M

EBS Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Emergent BioSolutions Inc.NYSE: EBS

Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026

Change in working capital declines year over year

Q1 FY2026 change in working capital of $51.8M (cash outflow) fell 56.4% year over year, behind the -34.1% change in trailing-twelve-month change in working capital. Over 3 fiscal years it compounded at +120.1% a year.

Context

  • Change in working capital amounted to 3.0% of revenue in FY2025, down 5.5 pp from a year earlier.
  • Change in working capital increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -56.4% toward the trailing-twelve-month pace of -34.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$51.8M-163.2% QoQ
Last fiscal yearDec 2025
-$22.4M-125.3% YoY
LTMMar 2026
$44.5M-34.1% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-56.4%——
1 year-125.3%——
3-year CAGR+120.1%——
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
(22.4M) USD
Year-over-year change
-125.3%

Change in Working Capital vs competitors

How EBS compares with its peers on the latest reported figures

  • Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -34.1% is the 8th highest of 11, against a peer median of -3.3%.
  • Change in working capital amounts to 6.6% of revenue for EBS, versus a peer median of 6.6%.
EBS Competitors
Change in Working Capital for EBS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EBSEmergent BioSolutions Inc.LTM Mar 2026$44.5M USD-34.1%+120.1%6.6%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$41.14M USD-15.9%+57.2%8.0%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$27.73M USD+3.9%+63.1%6.6%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$16.86M USD+244.6%-2.8%—
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$12.38M USD-10.5%-12.4%4.1%
CMPSCOMPASS Pathways plcLTM Mar 2026$7.8M USD-44.1%-22.5%—
PRTAProthena Corporation plcLTM Mar 2026$7.3M USD-87.4%-39.5%12.6%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$4.79M USD+137.1%-27.5%9.5%
SIGASIGA Technologies, Inc.LTM Mar 2026$3.91M USD-119.8%-4.4%4.2%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$3.48M USD+328.3%+36.3%—
SNDLSNDL Inc.LTM Mar 2026CA$278K CAD+109.0%—0.0%
Peer median (excluding EBS) —-3.3%-4.4%6.6%

Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income230.9M(211.6M)(760.5M)(190.6M)52.6M
Depreciation & Amortization123.8M143.3M125.1M108.8M95.8M
Deferred Income Tax46.9M(28.6M)(8.9M)(5.5M)(4M)
Stock-Based Compensation42.4M45.1M23.1M18M16.2M
Change in Working Capital(156.4M)(2.1M)(70.3M)88.7M(22.4M)
Accounts Receivables(48.2M)118.1M(21.6M)(24.4M)25.5M
Inventory(44M)(57.1M)600K(24.5M)(30.3M)
Accounts Payables(2.5M)(14M)10.6M(33M)(8.4M)
Other Working Capital(61.7M)(49.1M)(59.9M)170.6M(9.2M)
Other Non-Cash Items33.5M19.8M485.2M39.3M32.4M
Operating Cash Flow321.1M(34.1M)(206.3M)58.7M170.6M
Capital Expenditures(225M)(115.8M)(51.6M)(22.9M)(13.8M)
Acquisitions (Net)00270.2M00
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0(265.5M)(6.3M)148.1M83.2M
Investing Cash Flow(225M)(381.3M)212.3M125.2M69.4M
Debt Repayment(35.9M)564.2M(543.4M)(198.4M)(112.5M)
Common Stock Issued008.4M9.3M2.2M
Common Stock Repurchased(106M)(82.1M)00(24.9M)
Dividends Paid00000
Other Financing Activities900K(900K)(700K)(900K)(1.4M)
Financing Cash Flow(141M)481.2M(535.7M)(190M)(136.6M)
Effect of Forex Changes(300K)500K(1.2M)0100K
Net Change in Cash(45.2M)66.3M(530.9M)(6.1M)103.5M
Free Cash Flow96.1M(149.9M)(257.9M)35.8M156.8M

Emergent BioSolutions Inc.

NYSE:EBS

Intrinsic Alpha fair value

Locked

Current Price

$5.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.